Home>
US Stocks>
Biodexa Pharmaceuticals Plc

Biodexa Pharmaceuticals Plc share price today

(BDRX)

Biodexa Pharmaceuticals Plc share price is $4.29 & ₹365.50 as on 25 Dec 2024, 2.30 'hrs' IST

$4.29

▲

0.47

(12.29%)

Market is closed - opens 8 PM, 26 Dec 2024

View live Biodexa Pharmaceuticals Plc share price in Dollar and Rupees. Guide to invest in Biodexa Pharmaceuticals Plc from India. Also see the sentimental analysis on Indian investors investing in Biodexa Pharmaceuticals Plc. Get details on the Indian mutual funds that are investing in Biodexa Pharmaceuticals Plc. Get Analyst recommendations and forecasts along with all the Biodexa Pharmaceuticals Plc's financials.

Biodexa Pharmaceuticals Plc share price movements

Today's Low: $4.00
Today's High: $4.29
$4.29
6.76%
Downside
Day's Volatility :6.76%
Upside
0.0%
52 Weeks Low: $3.50
52 Weeks High: $74.00
$4.29
18.41%
Downside
52 Weeks Volatility :95.27%
Upside
94.2%

Biodexa Pharmaceuticals Plc Returns

Period	Biodexa Pharmaceuticals Plc	Index (Russel 2000)
3 Months	-41.84%	0.0%
6 Months	-80.3%	0.0%
1 Year	-93.32%	0.0%
3 Years	-99.54%	-21.1%

Biodexa Pharmaceuticals Plc Key Statistics

in dollars & INR

Previous Close	$3.82
Open	$4.1866
Today's High	$4.29
Today's Low	$4.0
Market Capitalization	$2.5M
Today's Volume	$6.7K
52 Week High	$73.9975
52 Week Low	$3.5
Revenue TTM	$83.0K
EBITDA	$-6.4M
Earnings Per Share (EPS)	$-75.2
Profit Margin	0.0%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-97.23%

How to invest in Biodexa Pharmaceuticals Plc from India?

It is very easy for Indian residents to invest directly in Biodexa Pharmaceuticals Plc from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Biodexa Pharmaceuticals Plc stock in both Indian Rupees (INR) and US Dollars (USD). Search for Biodexa Pharmaceuticals Plc or BDRX on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Biodexa Pharmaceuticals Plc or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Biodexa Pharmaceuticals Plc shares which would translate to 0.199 fractional shares of Biodexa Pharmaceuticals Plc as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Biodexa Pharmaceuticals Plc, in just a few clicks!

Returns in Biodexa Pharmaceuticals Plc for Indian investors in Rupees

Investment Value

₹1,00,000

Biodexa Pharmaceuticals Plc investment value today

Current value as on today

₹8,916

Returns

₹91,084

(-91.08%)

Returns from Biodexa Pharmaceuticals Plc Stock

₹93,323 (-93.32%)

Dollar Returns

₹2,239 (+2.24%)

Indian investors sentiment towards Biodexa Pharmaceuticals Plc

-37%

Period: Sep 26, 2024 to Dec 25, 2024. Change in 30 Days versus previous period

Search volume for Biodexa Pharmaceuticals Plc on INDmoney from India has reduced in the last 30 days as on Dec 26, 2024. -37% less investors are searching Biodexa Pharmaceuticals Plc in the last 30 days versus the previous period.

Analyst Recommendation on Biodexa Pharmaceuticals Plc

Buy

85%Buy

14%Hold

0%Sell

Based on 7 Wall street analysts offering stock ratings for Biodexa Pharmaceuticals Plc(by analysts ranked 0 to 5 stars)

Based on 7 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Biodexa Pharmaceuticals Plc

What analysts predicted

Upside of 4477.24%

Current:

$4.29

Target:

$196.36

Insights on Biodexa Pharmaceuticals Plc

Price Movement
In the last 3 months, BDRX stock has moved down by -41.8%
Decreasing Revenue
Revenue is down for the last 3 quarters, 149.0K → 41.5K (in $), with an average decrease of 36.1% per quarter
Increasing Net Profit
Netprofit is up for the last 7 quarters, -2.29M → -1.65M (in $), with an average increase of 6.1% per quarter
BDRX vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 27.2% return, outperforming this stock by 120.5%
Price to Sales
ForBDRX every $1 of sales, investors are willing to pay $9.9, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $14.7 for every $1 of sales.

Biodexa Pharmaceuticals Plc Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$1.9M	↑ 95.96%
Net Income	$-10.4M	↓ 11.42%
Net Profit Margin	-534.98%	↑ 648.54%

	FY19	Y/Y Change
Revenue	$882.5K	↓ 65.22%
Net Income	$-12.0M	↓ 11.86%
Net Profit Margin	-1.4K%	↓ 820.81%

	FY20	Y/Y Change
Revenue	$460.7K	↓ 49.11%
Net Income	$-29.8M	↑ 142.82%
Net Profit Margin	-6.5K%	↓ 5113.31%

	FY21	Y/Y Change
Revenue	$769.0K	↑ 68.51%
Net Income	$-7.3M	↓ 75.39%
Net Profit Margin	-944.64%	↑ 5524.46%

	FY22	Y/Y Change
Revenue	$850.9K	↑ 20.93%
Net Income	$-9.3M	↑ 40.22%
Net Profit Margin	-1.1K%	↓ 150.64%

	FY23	Y/Y Change
Revenue	$482.3K	↓ 45.49%
Net Income	$-9.0M	↓ 7.54%
Net Profit Margin	-1.9K%	↓ 762.73%

	Q1 FY23	Q/Q Change
Revenue	$180.8K	↑ 29.0%
Net Income	$-2.2M	↓ 22.35%
Net Profit Margin	-1.2K%	↑ 791.86%

	Q2 FY23	Q/Q Change
Revenue	$188.2K	↑ 0.0%
Net Income	$-2.3M	↑ 0.0%
Net Profit Margin	-1.2K%	↑ 0.0%

	Q3 FY23	Q/Q Change
Revenue	$41.5K	↓ 72.15%
Net Income	$-1.8M	↓ 1.6%
Net Profit Margin	-4.2K%	↓ 3032.8%

	Q4 FY23	Q/Q Change
Revenue	$41.5K	↑ 0.0%
Net Income	$-1.8M	↑ 0.0%
Net Profit Margin	-4.2K%	↑ 0.0%

	FY18	Y/Y Change
Profit	$-7.4M	↑ 1.1%

	FY19	Y/Y Change
Profit	$-9.4M	↓ 3.4%

	FY20	Y/Y Change
Profit	$-7.7M	↓ 20.14%

	FY21	Y/Y Change
Profit	$-5.4M	↓ 28.8%

	FY22	Y/Y Change
Profit	$-5.4M	↑ 8.24%

	FY23	Y/Y Change
Profit	$-4.7M	↓ 16.46%

	Q1 FY23	Q/Q Change
Profit	$-1.2M	↓ 20.84%

	Q2 FY23	Q/Q Change
Profit	$-1.2M	↑ 0.0%

	Q3 FY23	Q/Q Change
Profit	$-1.1M	↑ 11.01%

	Q4 FY23	Q/Q Change
Profit	$-1.1M	↑ 0.0%

	Q1 FY24	Q/Q Change
Profit	$-1.1M	↑ 0.97%

	Q2 FY24	Q/Q Change
Profit	$-1.1M	↑ 0.0%

	FY19	Y/Y Change
Operating Cash Flow	$-8.5M	↓ 51.75%
Investing Cash Flow	$-5.0M	-
Financing Cash Flow	$24.5M	↓ 389.45%

	FY20	Y/Y Change
Operating Cash Flow	$-12.5M	↑ 43.33%
Investing Cash Flow	$3.5M	↓ 167.61%
Financing Cash Flow	$4.1M	↓ 83.54%

	FY21	Y/Y Change
Operating Cash Flow	$-8.0M	↓ 35.4%
Investing Cash Flow	$-369.9K	↓ 110.8%
Financing Cash Flow	$11.7M	↑ 185.51%

	Q1 FY23	Q/Q Change
Operating Cash Flow	$-2.4M	↑ 10.6%
Investing Cash Flow	$12.1K	↑ 0.0%
Financing Cash Flow	$3.8M	↑ 4901.6%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-2.5M	↑ 0.0%
Investing Cash Flow	$12.6K	↑ 0.0%
Financing Cash Flow	$3.9M	↑ 0.0%

Biodexa Pharmaceuticals Plc Technicals Summary

Sell

Neutral

Buy

Biodexa Pharmaceuticals Plc is currently in a neutral trading position according to technical analysis indicators.

Biodexa Pharmaceuticals Plc Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Biodexa Pharmaceuticals Plc	-10.64%	-80.3%	-93.32%	-99.54%	-99.54%
Regeneron Pharmaceuticals, Inc.	-5.12%	-32.01%	-18.29%	12.56%	91.19%
Biontech Se	-3.72%	41.99%	6.11%	-55.22%	226.93%
Alnylam Pharmaceuticals, Inc.	-3.99%	-1.52%	23.75%	50.98%	112.09%
Vertex Pharmaceuticals Incorporated	-12.61%	-13.61%	0.03%	83.58%	86.41%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Biodexa Pharmaceuticals Plc	NA	NA	NA	-3.0	-0.97	-0.38	NA	24.07
Regeneron Pharmaceuticals, Inc.	17.67	17.67	1.06	45.07	0.17	0.07	NA	272.04
Biontech Se	160.8	NA	0.04	-3.11	-0.02	-0.01	NA	79.73
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-0.19	-15.01	-0.03	NA	0.25
Vertex Pharmaceuticals Incorporated	32.84	NA	1.06	0.51	-0.03	0.12	NA	60.65

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Biodexa Pharmaceuticals Plc	Buy	$2.5M	-99.54%	NA	0.0%
Regeneron Pharmaceuticals, Inc.	Buy	$78.5B	91.19%	17.67	33.61%
Biontech Se	Buy	$27.4B	226.93%	160.8	-15.36%
Alnylam Pharmaceuticals, Inc.	Buy	$31.4B	112.09%	NA	-15.86%
Vertex Pharmaceuticals Incorporated	Buy	$105.1B	86.41%	32.84	-4.51%

About Biodexa Pharmaceuticals Plc

midatech is a world leader in the design, synthesis and manufacture of biocompatible gold nanoparticles (gnps) with a core focus on therapeutics for diabetes and cancer. midatech has a strong pipeline of product candidates in clinical and pre-clinical development for the treatment of diabetes and various cancers. in 2012, midatech established midasol therapeutics lp, a strategic joint venture with monosol rx llc to focus on the development and commercialization, via partnering or licensing, of products primarily for the treatment of diabetes. midasol’s lead product, midaform™ insulin pharmfilm, is a unique product for the oral delivery of insulin in diabetic patients and will enter phase ii clinical studies in 2014. these technologies are also being evaluated in the diabetes area by a major us pharmaceutical company. midatech’s unique gnp technology enables the administration and targeted delivery of therapeutic compounds to specific cells and tissues. multiple drug molecules can b

Organization	Biodexa Pharmaceuticals Plc
Employees	21
CEO	Mr. Stephen A. Stamp
Industry	Miscellaneous

Management People of Biodexa Pharmaceuticals Plc

Name	Title
Mr. Stephen A. Stamp	CEO, CFO, Company Secretary & Director
Dr. Daniel Palmer MBA, Ph.D.	Vice President of Technology
Ms. Nicola Tuckwell	VP & Head of Clinical Operations
Mr. Steve Ellul	Chief Business Officer
Ms. Fiona Sharp	Group Financial Controller

Important FAQs about investing in Biodexa Pharmaceuticals Plc from India :

What is Biodexa Pharmaceuticals Plc share price today?

Biodexa Pharmaceuticals Plc share price today stands at $4.29, Open: $4.19 ; Previous Close: $3.82 ; High: $4.29 ; Low: $4.00 ; 52 Week High: $74.00 ; 52 Week Low: $3.50. The stock opens at $4.19, after a previous close of $3.82. The stock reached a daily high of $4.29 and a low of $4.00, with a 52-week high of $74.00 and a 52-week low of $3.50.

Can Indians buy Biodexa Pharmaceuticals Plc shares?

Yes, Indians can invest in the Biodexa Pharmaceuticals Plc (BDRX) from India.

With INDmoney, you can buy Biodexa Pharmaceuticals Plc at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Biodexa Pharmaceuticals Plc at zero transaction cost.

How can I buy Biodexa Pharmaceuticals Plc shares from India?

It is very easy to buy Biodexa Pharmaceuticals Plc from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Biodexa Pharmaceuticals Plc be purchased?

Yes, you can buy fractional shares of Biodexa Pharmaceuticals Plc with INDmoney app.

What are the documents required to start investing in Biodexa Pharmaceuticals Plc stocks?

To start investing in Biodexa Pharmaceuticals Plc, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Biodexa Pharmaceuticals Plc

Today’s highest price of Biodexa Pharmaceuticals Plc (BDRX) is $4.29.

Today’s lowest price of Biodexa Pharmaceuticals Plc (BDRX) is $4.00.

What is today's market capitalisation of Biodexa Pharmaceuticals Plc

Today's market capitalisation of Biodexa Pharmaceuticals Plc BDRX is 2.5M

What is the 52 Week High and Low Range of Biodexa Pharmaceuticals Plc

52 Week High
$74.00
52 Week Low
$3.50

What are the historical returns of Biodexa Pharmaceuticals Plc?

1 Month Returns
-10.64%
3 Months Returns
-80.3%
1 Year Returns
-93.32%
5 Years Returns
-99.54%

Who is the Chief Executive Officer (CEO) of Biodexa Pharmaceuticals Plc

Mr. Stephen A. Stamp is the current Chief Executive Officer (CEO) of Biodexa Pharmaceuticals Plc.

Discover More

Explore all